PPAR gamma 2 Prevents Lipotoxicity by Controlling Adipose Tissue Expandability and Peripheral Lipid Metabolism

Gema Medina‐Gómez(Addenbrooke's Hospital), Sarah L. Gray(Addenbrooke's Hospital), Laxman Yetukuri(VTT Technical Research Centre of Finland), Kenju Shimomura(University of Oxford), Sam Virtue(Addenbrooke's Hospital), Mark Campbell(University of Cambridge), Ruth Curtis(University of Cambridge), Mercedes Jimenez‐Liñan(University of Cambridge), Margaret Blount(University of Cambridge), Giles S.H. Yeo(Addenbrooke's Hospital), Miguel López(Addenbrooke's Hospital), Tuulikki Seppänen‐Laakso(VTT Technical Research Centre of Finland), Frances M. Ashcroft(University of Oxford), Matej Orešič(VTT Technical Research Centre of Finland), Antonio Vidal‐Puig(Addenbrooke's Hospital)
PLoS Genetics
April 25, 2007
Cited by 423Open Access
Full Text

Abstract

Peroxisome proliferator activated receptor gamma 2 (PPARg2) is the nutritionally regulated isoform of PPARg. Ablation of PPARg2 in the ob/ob background, PPARg2(-/-) Lep(ob)/Lep(ob) (POKO mouse), resulted in decreased fat mass, severe insulin resistance, beta-cell failure, and dyslipidaemia. Our results indicate that the PPARg2 isoform plays an important role, mediating adipose tissue expansion in response to positive energy balance. Lipidomic analyses suggest that PPARg2 plays an important antilipotoxic role when induced ectopically in liver and muscle by facilitating deposition of fat as relatively harmless triacylglycerol species and thus preventing accumulation of reactive lipid species. Our data also indicate that PPARg2 may be required for the beta-cell hypertrophic adaptive response to insulin resistance. In summary, the PPARg2 isoform prevents lipotoxicity by (a) promoting adipose tissue expansion, (b) increasing the lipid-buffering capacity of peripheral organs, and (c) facilitating the adaptive proliferative response of beta-cells to insulin resistance.


Related Papers

No related papers found

Powered by citation graph analysis